Furthermore, Gunawan et al. reported on a patient with CNL harboring compound CSF3R mutations (CSF3RT618I and CSF3RG739 truncation mutation) in whom treatment with Ruxolitinib induced hematological response in parallel with reductions in allelic burden for both mutations168. Here, CSF3R is linked to chronic neutrophilic leukemia.